Need harmonised standards for developing biosimiliar drugs: Susana Almeida, IGBA
Dr Susana Almeida, Secretary General, International Generic and Biosimilar Medicines Association (IGBA), speaks to Vikas Dandekar, Editor, ET Pharma, about the new concept of having harmonised standards for bioequivalence studies and guidelines for developing biosimilars. Dr Almeida discusses the difficulties faced in bioequivalence studies when there were no internationally harmonised standards. She highlights the role of Indian pharmaceutical companies in making treatments available beyond India and emphasises the scale that Indian companies have achieved and are capable of.
Source link
